Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis

Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 11, 2026, 07:30 ET Multi-target therapeutic aims to treat all key and interconnected problems of atopic dermatitis ANNAPOLIS, Md., March 11, 2026 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing the first Multi-Target…

Dermatology Times: Alphyn Expands Pipeline with Phase 2 Trial of Zabalafin Hydrogel for Molluscum Contagiosum

Dermatology Times: Alphyn Expands Pipeline with Phase 2 Trial of Zabalafin Hydrogel for Molluscum Contagiosum by Marie Bosslett NEWS PROVIDED BY Alphyn Biologics February 19, 2026 Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients. Read the Dermatology Times article here. CONTACTS   Corporate: Neal Koller…

First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum

First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics Feb 18, 2026, 07:30 ET New program expands pipeline derived from Alphyn’s proprietary multi-target drug platform ANNAPOLIS, Md., Feb. 18, 2026 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,…

Masters of Pediatric Dermatology 2026 Poster Presentation: S. aureus Contribution to the Etiology of Pediatric Atopic Dermatitis

Masters of Pediatric Dermatology 2026 Poster Presentation: S. aureus Contribution to the Etiology of Pediatric Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics February 5, 2026, 00:00 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Masters of Pediatric Dermatology 2026 Poster Presentation: Zabalafin, a Novel Topical Antiviral for the Treatment of Molluscum Contagiosum

Masters of Pediatric Dermatology 2026 Poster Presentation: Zabalafin, a Novel Topical Antiviral for the Treatment of Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics February 5, 2026, 00:00 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195